What the trial was testing
The FLASH-UK enrolled 156 patients with type 1 diabetes. The study was sponsored by Manchester University NHS Foundation Trust and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
Researchers followed patients through treatment and into recovery, tracking the outcomes that mattered most for the disease being studied.
What the results showed
The sensor group spent 130 more minutes per day in healthy blood sugar range.
The New England journal of medicine · 2022 · NCT03815006
These findings — that time spent in healthy blood sugar range vs. fingerstick testing — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 156 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 1 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
If your type 1 diabetes is hard to control with fingerstick testing, this sensor technology is FDA-approved and available now. It scans your glucose levels continuously and can alert you when you're going too high or too low. Talk to your doctor about whether continuous glucose monitoring is right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 1 diabetes trials
The iLet Experience Study
A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.